Pharma says high prices fund drug development. This study says otherwise By: MarketWatch March 08, 2017 at 11:08 AM EST Higher U.S. prices are generating far more revenue than the costs of research and development. Read More >> Related Stocks: Amgen Astrazeneca Plc ADR Biogen Idec Bristol-Myers Squibb Gilead Sciences Johnson & Johnson Merck & Co Pfizer Teva Pharmaceutical Industries ADR